BIGNUCOLO, ALESSIA
 Distribuzione geografica
Continente #
NA - Nord America 559
AS - Asia 82
EU - Europa 58
OC - Oceania 5
Totale 704
Nazione #
US - Stati Uniti d'America 559
CN - Cina 78
IT - Italia 30
FI - Finlandia 9
DE - Germania 6
AU - Australia 5
GB - Regno Unito 5
UA - Ucraina 3
HK - Hong Kong 2
IE - Irlanda 2
IN - India 2
HR - Croazia 1
NL - Olanda 1
SE - Svezia 1
Totale 704
Città #
Fairfield 107
Chandler 90
Ashburn 42
Cambridge 40
Seattle 36
Beijing 35
Woodbridge 34
Houston 22
Wilmington 21
Medford 15
Princeton 15
Padova 14
Des Moines 12
New York 12
Helsinki 9
San Diego 9
Ann Arbor 8
Cagliari 6
Roxbury 6
Jinan 5
Melbourne 5
London 4
Nanjing 4
Atglen 3
Dublin 2
Fuzhou 2
Hebei 2
Kharkiv 2
Kowloon 2
Norwalk 2
Shenyang 2
Taizhou 2
Atlanta 1
Boardman 1
Borås 1
Council Bluffs 1
Haikou 1
Hangzhou 1
Lutsk 1
Nanchang 1
Ogden 1
San Vito Al Tagliamento 1
Shanghai 1
Taiyuan 1
Tucson 1
Utrecht 1
Zagreb 1
Totale 585
Nome #
Genetic markers of the host to predict the efficacy of colorectal cancer targeted therapy 70
Pharmacogenomics of targeted agents for personalization of colorectal cancer treatment 63
FARMAPRICE: A Pharmacogenetic Clinical decision support system for precise and Cost-Effective Therapy 61
Genetic biomarkers for hepatocellular cancer risk in a caucasian population. 60
Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI 55
Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-related gastrointestinal toxicity in metastatic colorectal cancer patients 53
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice 51
Resveratrol in cancer patients: From bench to bedside 44
Il15ra and smad3 genetic variants predict overall survival in metastatic colorectal cancer patients treated with folfiri therapy: A new paradigm 42
PREEMPTIVE PHARMACOGENOMIC TESTING FOR PREVENTING ADVERSE DRUG REACTIONS (PREPARE): STATE OF ART AND PRELIMINARY RESULTS ON GENOTYPE ACTIONABILITY 39
Development of an Integrated Health IT Platform for a Precision Medicine Setting 36
Uso di marcatori farmacogenetici per migliorare la sicurezza e l'efficacia dei trattamenti antiblastici all'interno dello studio di implementazione delle linee guida PGx PREPARE 29
DEVELOPMENT OF AN INTEGRATED HEALTH IT PLATFORM FOR A PRECISE AND COST-EFFECTIVE THERAPY IN ONCOLOGY 29
SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy 24
Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results 23
Sex disparities in efficacy in covid-19 vaccines: A systematic review and meta-analysis 15
The Multiple Effects of Vitamin D against Chronic Diseases: From Reduction of Lipid Peroxidation to Updated Evidence from Clinical Studies 10
Evaluation of Concomitant Use of Anticancer Drugs and Herbal Products: From Interactions to Synergic Activity 9
Integrative oncology: evidence-based medicine - The multidisciplinary experience of the Integrative Medicine Research Group (IMRG) 9
Totale 722
Categoria #
all - tutte 3.626
article - articoli 3.386
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.012


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020132 0 0 0 0 0 0 27 22 28 35 20 0
2020/2021106 11 1 26 1 19 3 3 0 26 3 4 9
2021/2022175 2 33 15 7 5 8 18 14 7 7 16 43
2022/2023173 28 20 1 18 29 27 0 14 18 1 16 1
2023/2024136 4 11 18 11 8 38 20 20 2 4 0 0
Totale 722